Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 5/20 | 0.53 |
| ▸ | MMP1 | P03956 | 4/20 | 0.53 |
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | MMP3 | P08254 | 4/20 | 0.53 |
| ▸ | MMP7 | P09237 | 4/20 | 0.53 |
| ▸ | MMP9 | P14780 | 4/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | EEF2K | O00418 | 2/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323240 | 1.00 | MMP13 (0.53) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL8277063 | 0.82 | MMP13 (0.60) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL6323466 | 0.80 | CA2 (0.68) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL6323465 | 0.80 | CA2 (0.68) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL6329763 | 0.79 | CA2 (0.54) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL6326224 | 0.79 | NR3C1 (0.51) | CA12CA2CA9ALDH1A1TSHR | |
| SCHEMBL6329758 | 0.79 | CA2 (0.54) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL6320955 | 0.79 | CA2 (0.53) | MMP13MMP1MMP2MMP9CA12 | |
| SCHEMBL6323690 | 0.79 | CA2 (0.53) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL6324072 | 0.79 | MMP2 (0.53) | MMP13MMP1MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | MMP13 2/4885MMP1 13/4885MMP2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.